Clinical management of hereditary breast cancer syndromes

Journal of Mammary Gland Biology and Neoplasia

Volumn 16, Issue 1, 2011, Pages 17-25

  Clark, Amy S ^a   Domchek, Susan M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Mastectomy; Oophorectomy; Ovarian cancer; PARP

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; METHOTREXATE; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHEMOTHERAPY INDUCED EMESIS; COWDEN SYNDROME; DYSGEUSIA; FAMILIAL CANCER; FATIGUE; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOTE; HUMAN; NAUSEA; OVARY CANCER; RISK REDUCTION; SALPINGOOOPHORECTOMY; TREATMENT RESPONSE;

BREAST NEOPLASMS; BREAST SELF-EXAMINATION; EARLY DETECTION OF CANCER; EARLY DIAGNOSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; NEOPLASTIC SYNDROMES, HEREDITARY;

EID: 79959587205     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-011-9200-x     Document Type: Article

References (113)

1. Jemal A et al. Cancer Statistics, 2010. CA Cancer J Clin 2010.
2. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11(2):103-5. (Pubitemid 46209856)
3. Miki Y et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71. (Pubitemid 24345325)
4. Wooster R et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-92. (Pubitemid 26004412)
5. Ford D et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-89. (Pubitemid 28164626)
6. Malone KE et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006;66(16):8297-308. (Pubitemid 44299201)
7. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864-74. (Pubitemid 44453442)
8. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991;48(2):232-42. (Pubitemid 21891587)
9. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57(6):1457-62.
10. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60(3):496-504. (Pubitemid 27097597)
11. Risch HA et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694-706. (Pubitemid 44942707)
12. Metcalfe KA et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28 (3):387-91.
13. Begg CB et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299(2):194-201.
14. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-33. (Pubitemid 46706879)
15. Antoniou A et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-30. (Pubitemid 36530000)
16. Gayther SA et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995;11(4):428-33.
17. Gayther SA et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15(1):103-5. (Pubitemid 27014960)
18. Antoniou AC et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70 (23):9742-54.
19. Antoniou AC et al. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18(2):173-90. (Pubitemid 30100077)
20. Brose MS et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365-72. (Pubitemid 35154141)
21. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91(15):1310-6.
22. Kadouri L et al. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet. 2007;44(7):467-71. (Pubitemid 47056875)
23. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358-65. (Pubitemid 35154140)
24. Tai YC et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811-4. (Pubitemid 351767200)
25. Roa BB et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14 (2):185-7. (Pubitemid 26338801)
26. Robson M et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test. 1997;1 (1):47-51. (Pubitemid 127526937)
27. Palma MD et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res. 2008;68(17):7006-14.
28. Walsh T et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295(12):1379-88.
29. Leach MO et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769-78. (Pubitemid 40744657)
30. Kriege M et al. Efficacy of MRI and mammography for breastcancer screening inwomen with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427-37.
31. Kuhl C et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28 (9):1450-7.
32. Rijnsburger AJ et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010;28(36):5265-73.
33. van der Velde NM et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer. 2009;124(4):919-23.
34. Vogel VG et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-41.
35. Fisher B et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97 (22):1652-62. (Pubitemid 41672231)
36. King MC et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251-6.
37. Gronwald J et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118 (9):2281-4.
38. Narod SA et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94(23):1773-9. (Pubitemid 36004353)
39. Whittemore AS et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer. 2004;91(11):1911-5. (Pubitemid 40065520)
40. Brohet RM et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 2007;25(25):3831-6. (Pubitemid 47477257)
41. Haile RW et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomark Prev. 2006;15(10):1863-70. (Pubitemid 44664261)
42. Hartmann LC et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-7. (Pubitemid 33094870)
43. Meijers-Heijboer H et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-64. (Pubitemid 32662123)
44. Kaas R et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010;251(3):488-92.
45. Domchek SM et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-75.
46. Kramer JL et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol. 2005;23(34):8629-35. (Pubitemid 46211505)
47. Kauff ND et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331-7.
48. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-7.
49. Eisen A et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491-6. (Pubitemid 46291812)
50. Finch A et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185-92.
51. Kauff ND et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346 (21):1609-15. (Pubitemid 34755668)
52. Rutter JL et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst. 2003;95(14):1072-8. (Pubitemid 36950111)
53. Rebbeck TR et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346 (21):1616-22. (Pubitemid 34755669)
54. Domchek SM et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006;7(3):223-9. (Pubitemid 43286452)
55. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222-31.
56. Parker WH et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009;113(5):1027-37.
57. Rocca WA et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821-8. (Pubitemid 44464065)
58. Madalinska JB et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol. 2006;24 (22):3576-82. (Pubitemid 46630529)
59. Rebbeck TR et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23 (31):7804-10. (Pubitemid 46657377)
60. Eisen A et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100(19):1361-7.
61. Rennert G et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357 (2):115-23. (Pubitemid 47057729)
62. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCAassociated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2010;119(1):13-24.
63. Tutt A et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-44.
64. Byrski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375-9.
65. Silver DP et al. Efficacy of neoadjuvant Cisplatin in triplenegative breast cancer. J Clin Oncol. 2010;28(7):1145-53.
66. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004;26(8):882-93. (Pubitemid 39128102)
67. Dantzer F et al. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry. 2000;39(25):7559-69. (Pubitemid 30422075)
68. McCabe N et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109-15. (Pubitemid 44299177)
69. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785-90.
70. Farmer H et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434 (7035):917-21. (Pubitemid 40559006)
71. Bryant HE et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-7. (Pubitemid 40559005)
72. Fong PC et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361 (2):123-34.
73. Audeh MW et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-51.
74. Lustbader ED et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet. 1992;51(2):344-56.
75. Garber KSaJ. Li-Fraumeni Syndrome in SBLA (Sarcoma, Breast, Leukemia and Adrenal Gland), B.T. Pagon RA, Dolan CR et al., Editor. GeneReviews: Seattle 2010.
76. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21(3):313-20. (Pubitemid 36292974)
77. Birch JM et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54(5):1298-304. (Pubitemid 24108072)
78. Gonzalez KD et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27(8):1250-6.
79. Bougeard G et al. Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene. 2003;22(6):840-6. (Pubitemid 36255819)
80. Achatz MI, Hainaut P, Ashton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol. 2009;10 (9):920-5.
81. Gonzalez KD et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46(10):689-93.
82. Hwang SJ et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003;72(4):975-83.
83. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004;23(38):6445-70. (Pubitemid 39265509)
84. Kleihues P et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150 (1):1-13. (Pubitemid 27027090)
85. Olivier M et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643-50. (Pubitemid 37322942)
86. Krutilkova V et al. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer. 2005;41 (11):1597-603. (Pubitemid 40981842)
87. Chompret A et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82 (12):1932-7. (Pubitemid 30326453)
88. Nichols KE et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomark Prev. 2001;10(2):83-7. (Pubitemid 32172424)
89. Wong P et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology. 2006;130(1):73-9. (Pubitemid 43049837)
90. Borresen AL et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992;52(11):3234-6.
91. Sidransky D et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52(10):2984-6.
92. Lalloo F et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet. 2003;361(9363):1101-2. (Pubitemid 36369565)
93. Masciari S et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008;299(11):1315-9. (Pubitemid 351439077)
94. Salmon A et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol R Coll Radiol. 2007;19 (7):490-3. (Pubitemid 47181183)
95. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000;37(11):828-30.
96. Scheper MA et al. Cowden syndrome: report of a case with immunohistochemical analysis and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101 (5):625-31. (Pubitemid 43621512)
97. Liaw D et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16(1):64-7. (Pubitemid 27198157)
98. Tate G et al. A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer. Cancer Genet Cytogenet. 2008;184(1):67-71. (Pubitemid 351814974)
99. Reifenberger J et al. Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. Br J Dermatol. 2003;148(5):1040-6. (Pubitemid 36750802)
100. Zhou XP et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet. 2003;73(2):404-11.
101. De Vivo I et al. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J Med Genet. 2000;37(5):336-41. (Pubitemid 30261264)
102. Teresi RE et al. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet. 2007;81(4):756-67. (Pubitemid 47596543)
103. Marsh DJ et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7(3):507-15. (Pubitemid 28120643)
104. Nelen MR et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7(3):267-73. (Pubitemid 29213732)
105. Farooq A et al. Cowden syndrome. Cancer Treat Rev. 2010;36 (8):577-83.
106. Ni Y et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet. 2008;83(2):261-8.
107. Lynch ED et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet. 1997;61(6):1254-60. (Pubitemid 28046900)
108. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer. 1978;41(6): 2393-8. (Pubitemid 8375545)
109. Nusbaum R, Vogel KJ, Ready K. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. Breast Dis. 2006;27:21-50.
110. Tsou HC et al. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet. 1997;61(5):1036-43. (Pubitemid 27492310)
111. Starink TM et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986;29(3):222-33.
112. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009;11(10):687-94.
113. Nelson HD et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009;151(10):703-15. W-226-35.